Tan J
Department of Medicine, University of Western Ontario, London, ON, Canada.
Skin Therapy Lett. 2012 Sep;17(8):1-3.
Dapsone 5% gel for the topical treatment for acne vulgaris was recently introduced in Canada. It represents the first new anti-acne agent to gain North American regulatory approval in the past decade. Dapsone's utility is attributable to its anti-inflammatory and antimicrobial properties that improve both inflammatory and non-inflammatory acne, with more prominent effects occurring in inflammatory lesions. Short- and long-term safety and efficacy have been demonstrated. Especially for patients exhibiting sensitivities or intolerance to conventional anti-acne agents, topical dapsone is a novel addition to the treatment armamentarium.
5%氨苯砜凝胶最近在加拿大被用于寻常痤疮的局部治疗。它是过去十年中首个获得北美监管批准的新型抗痤疮药物。氨苯砜的效用归因于其抗炎和抗菌特性,这些特性可改善炎性和非炎性痤疮,对炎性皮损的效果更为显著。已证明其短期和长期的安全性及有效性。特别是对于对传统抗痤疮药物表现出敏感或不耐受的患者,局部用氨苯砜是治疗手段中的一种新选择。